ILMN vs PACB: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ILMN is the larger of the two ($32.61B market cap): the incumbent the market prices for continued execution (34.88x forward earnings, beta 1.45). PACB is the smaller challenger ($691.60M), priced similarly on forward earnings (-5.33x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

ILMN vs PACB: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricILMNPACBWhat it tells you
Market cap$32.61B$691.60MSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E34.88-5.33Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.452.20Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range52% of range49% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.

Before you buy: how ILMN and PACB affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ILMN and PACB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ILMN and PACB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Illumina (ILMN) do?

Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Its business follows a razor-and-blades model: instruments such as the high-throughput NovaSeq X, the NextSeq, and the benchtop MiSeq seed an installed base, and the bulk of revenue then comes from recurring sequencing consumables (reagents and flow cells), which historically make up the majority of sales. The company is also pushing into multiomics, proteomics, and clinical diagnostics to expand what its platforms can measure. Illumina is headquartered in San Diego, was founded in 1998, and is led by CEO Jacob Thaysen.

Full ILMN guide

What does Pacific Biosciences of California (PACB) do?

Pacific Biosciences of California makes DNA sequencing systems built around its HiFi long-read technology, which reads long, highly accurate stretches of DNA. Its high-throughput Revio system serves production genomics labs generating reference-quality genomes, while the newer benchtop Vega, a smaller and much cheaper instrument, aims to put HiFi long reads on more lab benches and introduce new users to the platform. Like most sequencing companies, PacBio runs a razor-and-blade model: it sells instruments, then earns recurring, higher-margin revenue from the consumables and reagents customers buy to run them. Over the trailing twelve months through June 2026 revenue was about $159 million, roughly 2% lower year over year, with quarterly sales stuck in a $37 million to $45 million band.

Full PACB guide

ILMN vs PACB: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • ILMN drivers: Installed base and the consumables annuity; The NovaSeq X transition.
  • PACB drivers: HiFi long-read differentiation; Vega benchtop and installed-base growth.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. For PACB, the dominant risk is that PacBio is unprofitable and burning cash: it lost about $131 million over the trailing twelve months, used roughly $118 million in operating cash, and carries about $709 million of debt against roughly $237 million of cash, so it depends on reaching breakeven before that cushion is stressed.

ILMN or PACB: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ILMN if you believe its drivers more; PACB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ILMN and PACB guides.

ILMN vs PACB: the full fundamentals

ILMN. Illumina's multiple has expanded far faster than its earnings: the shares are up about 94% year to date and 172% over a year, while consensus calls for 2026 revenue growth near 11% and EPS of about $5.36. At roughly 43 times forward earnings and 36 times EV/EBITDA, the price assumes growth and margin expansion continue well beyond 2026, and the stock sits above the $241 average analyst target even as individual targets, such as JPMorgan's move to $320, have risen.

PACB. Figures are approximate and tied to the asOf date; verify live numbers before acting. Because PacBio is unprofitable, P/E does not apply, and at about 3.5 times trailing sales the stock is valued on whether revenue can grow again (consensus looks for about 19% growth in 2027) and how fast losses shrink relative to a cash balance that is smaller than its debt. Instrument placements, consumables pull-through and the November 4 report matter far more than any single accounting figure, which keeps the stock volatile.

Headline figures (approximate, October 2026): ILMN shows revenue (ttm) ~$4.49 billion; Q2 2026 revenue ~$1.16 billion, up ~9% year over year, 2026 revenue consensus ~$4.62 billion (~11% growth); 2027 consensus ~$4.92 billion, margins (ttm) Gross ~68%, operating ~21%, net ~18%, net income and eps (ttm) ~$824 million net income; EPS ~$5.39 trailing, ~$6.12 forward; PACB shows revenue (ttm) ~$159 million, down ~2% year over year, latest quarter (q2 2026) Revenue ~$39.0 million; loss $0.14 per share vs ~$0.13 expected, net income (ttm) Loss of ~$131 million; trailing EPS ~-$0.43, gross margin (ttm) ~29%; operating margin deeply negative.

The bottom line: ILMN vs PACB

ILMN and PACB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ILMN and PACB exposure against your real portfolio. It is not an investment adviser.

Wondering how ILMN or PACB fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Illumina

Ask Walnut's AI anything about ILMN and see how it fits what you own.

FAQ

What is the difference between ILMN and PACB?

+

Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Pacific Biosciences of California makes DNA sequencing systems built around its HiFi long-read technology, which reads long, highly accurate stretches of DNA. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ILMN or PACB the better stock?

+

Neither is universally better. ILMN is the larger incumbent; PACB is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ILMN or PACB?

+

On forward P/E (as of November 2026), ILMN trades at 34.88x and PACB at -5.33x, so PACB is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ILMN and PACB?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ILMN vs PACB?

+

ILMN: Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The underlying sequencing market is growing slowly, and soft academic and research funding, including pressure on US research budgets, can delay instrument purchases. China is now only about 3% of revenue after Illumina was effectively shut out of that market, where domestic players BGI and MGI dominate. Tariffs and a relatively high valuation add further risk. Valuation is now a larger part of the risk: at about 48 times trailing earnings and roughly 8.8 times sales after a 94% gain in 2026, the stock trades above the average analyst target of about $241, and the consensus for the third quarter calls for EPS of about $1.36 on revenue of about $1.15 billion, roughly 1% growth. A recall listing for the NovaSeq 6000Dx server correction is a reminder that clinical instruments carry regulatory exposure. PACB: The dominant risk is that PacBio is unprofitable and burning cash: it lost about $131 million over the trailing twelve months, used roughly $118 million in operating cash, and carries about $709 million of debt against roughly $237 million of cash, so it depends on reaching breakeven before that cushion is stressed. Growth has stalled, with trailing revenue down about 2% and full-year consensus near $159 million, below the $165 million to $175 million range guided earlier in 2026. Demand is exposed to academic and government research funding, which has been weak and is largely outside the company's control, pressuring instrument sales. Competition is intense: Oxford Nanopore leads the benchtop long-read market Vega is entering, and Illumina dominates the far larger short-read market, so PacBio must keep winning on technology and price. Vega promotional pricing and component costs have weighed on margins, and as a sub-$2 small-cap genomics stock PACB is highly volatile (its 52-week range runs from about $1.07 to $3.44), sensitive to each quarter's placements, guidance revisions, insider sales, and shifts in research budgets.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ILMN or PACB; figures are approximate and dated (as of November 2026). Verify current data before investing.